SiriusXM Faces Headwinds From Pricing Shift, Ad Weakness, Says JPMorgan

JP Morgan analyst warns SiriusXM faces revenue dilution and margin compression due to demographic shifts, lower-priced plans, and ad revenue decline. Latest Ratings for SIRI Date Firm Action From To Jan 2022 JP Morgan Downgrades Neutral Underweight Jan 2022 Wells Fargo Downgrades Overweight Equal-Weight Nov 2021 Barclays Downgrades Equal-Weight Underweight View More Analyst Ratings for…

Read More

Avalo Therapeutics ‘Represents An Attractive Pure-Play,’ Analyst Initiates Coverage With Over 300% Stock Upside

Avalo Therapeutics’ AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. Latest Ratings for AVTX Date Firm Action From To Mar 2022 Jefferies Downgrades Buy Hold Mar 2022 RBC Capital Maintains Outperform Sep 2021 RBC Capital Initiates Coverage On Outperform View More Analyst…

Read More